226 related articles for article (PubMed ID: 21815111)
1. Diagnosis and treatment of follicular lymphoma.
Hitz F; Ketterer N; Lohri A; Mey U; Pederiva S; Renner C; Taverna C; Hartmann A; Yeow K; Bodis S; Zucca E
Swiss Med Wkly; 2011; 141():w13247. PubMed ID: 21815111
[TBL] [Abstract][Full Text] [Related]
2. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
4. Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?
Rueda A; Casanova M; Redondo M; Pérez-Ruiz E; Medina-Pérez A
BMC Cancer; 2012 May; 12():210. PubMed ID: 22650448
[TBL] [Abstract][Full Text] [Related]
5. Follicular lymphoma.
Ghielmini M
Ann Oncol; 2010 Oct; 21 Suppl 7():vii151-3. PubMed ID: 20943608
[TBL] [Abstract][Full Text] [Related]
6. [Advances in management of follicular lymphoma].
Zinzani PL
Rinsho Ketsueki; 2014 Oct; 55(10):1937-40. PubMed ID: 25297758
[No Abstract] [Full Text] [Related]
7. Follicular lymphoma: emerging therapeutic strategies.
Kenkre VP; Kahl BS
Expert Rev Hematol; 2010 Aug; 3(4):485-95. PubMed ID: 21083037
[TBL] [Abstract][Full Text] [Related]
8. Follicular lymphoma: 2011 update on diagnosis and management.
Freedman A
Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
[TBL] [Abstract][Full Text] [Related]
9. Open questions in watchful waiting for follicular lymphoma.
Sorigue M; Sancho JM; Ribera JM
Br J Haematol; 2017 Nov; 179(4):679-681. PubMed ID: 27390920
[No Abstract] [Full Text] [Related]
10. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
11. Maintenance rituximab should be considered for patients with follicular lymphoma.
Barr PM
Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
[No Abstract] [Full Text] [Related]
12. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
13. [Follicular lymphoma].
Tomita N
Nihon Rinsho; 2014 Mar; 72(3):488-92. PubMed ID: 24724409
[TBL] [Abstract][Full Text] [Related]
14. Follicular lymphoma: today's treatments and tomorrow's targets.
Aurora V; Winter JN
Expert Opin Pharmacother; 2006 Jul; 7(10):1273-90. PubMed ID: 16805715
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
Solal-Céligny P; Leconte P; Bardet A; Hernandez J; Troussard X
Br J Haematol; 2018 Jan; 180(2):217-223. PubMed ID: 29230799
[TBL] [Abstract][Full Text] [Related]
16. Rituximab maintenance therapy of relapsed or refractory follicular lymphoma, with longer follow-up: no proven impact on survival.
Prescrire Int; 2012 Mar; 21(125):63. PubMed ID: 22428183
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
18. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
[TBL] [Abstract][Full Text] [Related]
19. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
20. Current immunochemotherapy strategies in follicular lymphoma.
Giné E; Gutiérrez-García G; López-Guillermo A
Adv Ther; 2010 Oct; 27(10):704-13. PubMed ID: 20820973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
